Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Amicus Therapeutics Q3 Adj. EPS $0.17 Beats $0.04 Estimate, Sales $169.061M Beat $165.706M Estimate

Author: Benzinga Newsdesk | November 04, 2025 07:02am
Amicus Therapeutics (NASDAQ:FOLD) reported quarterly earnings of $0.17 per share which beat the analyst consensus estimate of $0.04 by 335.9 percent. This is a 70 percent increase over earnings of $0.10 per share from the same period last year. The company reported quarterly sales of $169.061 million which beat the analyst consensus estimate of $165.706 million by 2.02 percent. This is a 19.46 percent increase over sales of $141.517 million the same period last year.

Posted In: FOLD


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist